Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Source: View publication →
The Phase III POSEIDON trial demonstrated that adding a limited course of the CTLA-4 inhibitor tremelimumab to the PD-L1 inhibitor durvalumab and platinum-based chemotherapy significantly improved progression-free and overall survival compared to chemotherapy alone in first-line metastatic non-small cell lung cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The POSEIDON trial provided pivotal evidence leading to the FDA approval of tremelimumab combined with durvalumab and platinum-based chemotherapy as a first-line treatment for adults with metastatic NSCLC lacking sensitizing EGFR or ALK genomic tumor aberrations. By utilizing a limited, five-dose course of tremelimumab, the regimen successfully enhanced the depth and durability of responses while maintaining a manageable safety profile. Post-hoc exploratory analyses further revealed notable clinical benefits in historically difficult-to-treat subgroups, such as patients with KRAS, STK11, and KEAP1 mutations.
Historical Context
The treatment landscape for metastatic non-small cell lung cancer (NSCLC) was revolutionized by the introduction of immune checkpoint inhibitors, specifically PD-1/PD-L1 inhibitors combined with platinum-doublet chemotherapy, establishing new standards of care (e.g., KEYNOTE-189, KEYNOTE-407, IMpower150). Concurrently, dual checkpoint blockade combining CTLA-4 and PD-1/PD-L1 inhibition emerged to further enhance T-cell priming and combat resistance, as seen in CheckMate 9LA. The POSEIDON trial sought to build on this paradigm by evaluating a limited 'burst' schedule of tremelimumab (anti-CTLA-4) alongside durvalumab (anti-PD-L1) and standard chemotherapy, aiming to secure robust long-term survival while mitigating the high toxicity conventionally associated with continuous dual immunotherapy.
Guided Discussion
High-yield insights from every perspective
What is the mechanistic rationale for combining a CTLA-4 inhibitor (tremelimumab) with a PD-L1 inhibitor (durvalumab) in the treatment of metastatic NSCLC, and at what different phases of the T-cell immune response do these two checkpoints operate?
Key Response
CTLA-4 primarily functions in the lymph nodes during the initial 'priming' phase of T-cell activation by competing with CD28 for B7 ligands, thereby halting T-cell proliferation. Conversely, PD-L1/PD-1 interaction occurs primarily in the peripheral tumor microenvironment during the 'effector' phase, leading to T-cell exhaustion. Combining these agents provides a synergistic, dual blockade that enhances initial T-cell activation while simultaneously preventing their deactivation at the tumor site.
The POSEIDON trial utilized a 'limited course' of tremelimumab alongside durvalumab and chemotherapy. Clinically, how does the addition of a CTLA-4 inhibitor change the expected toxicity profile compared to PD-(L)1 inhibition alone, and what was the clinical rationale for limiting the tremelimumab doses?
Key Response
CTLA-4 inhibitors are notoriously associated with higher rates and greater severity of immune-related adverse events (irAEs), such as colitis and hypophysitis, compared to PD-1/PD-L1 inhibitors. Limiting the course of tremelimumab (to up to 5 doses) aims to achieve the early immunological 'priming' benefit of CTLA-4 blockade while mitigating the long-term, dose-dependent severe toxicities, resulting in a more tolerable triplet regimen for patients.
In reviewing the exploratory subgroup analyses of the POSEIDON trial, particularly regarding patients with STK11, KEAP1, or KRAS mutations, how does the triplet regimen of durvalumab, tremelimumab, and chemotherapy potentially overcome the immunoresistance classically seen in these hard-to-treat genomic subsets?
Key Response
STK11 and KEAP1 mutations in NSCLC are traditionally associated with a 'cold' tumor microenvironment, poor T-cell infiltration, and primary resistance to single-agent PD-(L)1 blockade. The POSEIDON data suggested that adding CTLA-4 inhibition drives robust peripheral T-cell priming and infiltration, demonstrating a promising overall survival signal in these specific refractory subgroups compared to durvalumab plus chemotherapy or chemotherapy alone, offering a critical targeted strategy.
With multiple frontline chemo-immunotherapy regimens now approved for mNSCLC (e.g., pembrolizumab plus chemotherapy, nivolumab plus ipilimumab plus chemotherapy), how do you weigh the POSEIDON regimen in clinical practice, and which specific patient phenotypes are you most likely to select for this durvalumab/tremelimumab triplet?
Key Response
Selecting a frontline regimen requires balancing efficacy, toxicity, and schedule. The POSEIDON triplet is particularly attractive for patients with PD-L1 negative tumors or those with STK11/KEAP1 co-mutations where single-checkpoint blockade often falls short. The limited-course tremelimumab offers a middle ground, providing the benefit of dual checkpoint inhibition while potentially avoiding the continuous toxicity seen with ongoing CTLA-4 administration in other regimens.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The POSEIDON trial employed a complex alpha-spending and hierarchical testing strategy to evaluate both progression-free and overall survival across two experimental arms versus the control arm. How did this hierarchical design protect the family-wise error rate, and what are the statistical implications for interpreting the durvalumab plus chemotherapy doublet arm?
Key Response
Trials with multiple experimental arms must control for Type I error using alpha allocation (e.g., splitting alpha between PFS and OS, and between the triplet and doublet arms). In hierarchical testing, if a higher-order test fails to reach statistical significance, subsequent downstream tests cannot be formally claimed as statistically significant, even if their nominal p-values are low. Understanding this rigid hierarchy prevents the over-interpretation of efficacy in secondary experimental arms.
From an editorial perspective, a major critique of the POSEIDON trial is the choice of the control arm (chemotherapy alone) in an era where pembrolizumab plus chemotherapy was rapidly becoming the standard of care. How does this shifting baseline impact the internal validity versus the external clinical relevance of the trial's effect size?
Key Response
While the trial maintains internal validity by properly randomizing against the protocol-defined standard at its inception (chemotherapy), the lack of a contemporary chemo-immunotherapy control arm drastically affects external validity. This shifting standard makes the comparative effectiveness of the new triplet regimen challenging to definitively establish against modern baselines, a classic threat to the translational impact of long-running Phase III trials that a reviewer must highlight.
Based on the POSEIDON findings, what level of evidence and strength of recommendation should be assigned to the durvalumab, tremelimumab, and chemotherapy combination in first-line mNSCLC guidelines, and how should it be positioned relative to the existing Category 1 recommendation for pembrolizumab plus chemotherapy?
Key Response
The regimen warrants a Category 1 recommendation based on the robust Phase III overall survival benefit. However, due to the lack of head-to-head data against standard chemo-IO (like KEYNOTE-189), guidelines should position it as an alternative frontline option rather than a replacement. Committees should specifically highlight its utility in subpopulations (e.g., PD-L1 <1%, STK11/KEAP1 mutants) where dual checkpoint inhibition may offer a distinct mechanistic advantage over single-agent PD-(L)1 regimens.
Clinical Landscape
Noteworthy Related Trials
KEYNOTE-189
Tested
Pembrolizumab + pemetrexed + platinum chemotherapy
Population
Treatment-naive metastatic non-squamous NSCLC without EGFR/ALK mutations
Comparator
Placebo + pemetrexed + platinum chemotherapy
Endpoint
Overall survival (OS) and Progression-free survival (PFS)
CheckMate 227
Tested
Nivolumab + ipilimumab
Population
Treatment-naive advanced NSCLC without EGFR/ALK mutations
Comparator
Platinum-doublet chemotherapy
Endpoint
Overall survival (OS) in patients with PD-L1 of 1% or more
CheckMate 9LA
Tested
Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy
Population
Treatment-naive metastatic NSCLC
Comparator
Platinum-doublet chemotherapy (4 cycles)
Endpoint
Overall survival (OS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis